Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PDE Inhibitors for the Treatment of Schizophrenia
Gretchen L. Snyder, Kimberly E. Vanover
Advances in neurobiology (2017), pp. 385-409
Closed Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders
Alexander S. Hatoum, Sarah M. C. Colbert, Emma C. Johnson, et al.
Nature Mental Health (2023) Vol. 1, Iss. 3, pp. 210-223
Open Access | Times Cited: 126
Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development
Alice Egerton, Anthony A. Grace, James Stone, et al.
Schizophrenia Research (2020) Vol. 223, pp. 59-70
Open Access | Times Cited: 83
Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders
Abid Bhat, Bipul Ray, Arehally M. Mahalakshmi, et al.
Pharmacological Research (2020) Vol. 160, pp. 105078-105078
Closed Access | Times Cited: 81
Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules
Andrey D. Bondarev, Misty M. Attwood, Jörgen Jönsson, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 43
Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds
Letizia Biso, Marco Carli, Marco Scarselli, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 85-85
Open Access | Times Cited: 1
Multi-Target Approach for Drug Discovery against Schizophrenia
Magda Kondej, Piotr Stępnicki, Agnieszka A. Kaczor
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 10, pp. 3105-3105
Open Access | Times Cited: 79
GenomeMUSter mouse genetic variation service enables multitrait, multipopulation data integration and analysis
Robyn L. Ball, Molly A. Bogue, Hongping Liang, et al.
Genome Research (2024) Vol. 34, Iss. 1, pp. 145-159
Open Access | Times Cited: 7
Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments
Antón L. Martínez, José Brea, Sara Rico, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 9905-9905
Open Access | Times Cited: 34
Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders
Alexander S. Hatoum, Sarah M. C. Colbert, Emma C. Johnson, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 27
New pharmacological approaches in the treatment of schizophrenia
Józef Muszyński, Agnieszka Bienert, Rasha Wafaie Mahmoud Elsorady, et al.
Pharmacological Reports (2025)
Closed Access
Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3β/β-catenin pathway
Hebatalla I. Ahmed, Somaia A. Abdel-Sattar, Heba S. Zaky
Naunyn-Schmiedeberg s Archives of Pharmacology (2018) Vol. 391, Iss. 12, pp. 1327-1338
Closed Access | Times Cited: 32
Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review
Amanda Garrido, Gonzalo Vera, Pierre‐Olivier Delaye, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113867-113867
Open Access | Times Cited: 24
Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder
Rui-Ting Wen, Fang-Fang Zhang, Han‐Ting Zhang
Psychopharmacology (2018) Vol. 235, Iss. 6, pp. 1793-1805
Open Access | Times Cited: 24
Roflumilast, a cAMP-Specific Phosphodiesterase-4 Inhibitor, Reduces Oxidative Stress and Improves Synapse Functions in Human Cortical Neurons Exposed to the Excitotoxin Quinolinic Acid
Abid Bhat, Vanessa Tan, Benjamin Heng, et al.
ACS Chemical Neuroscience (2020) Vol. 11, Iss. 24, pp. 4405-4415
Closed Access | Times Cited: 18
Selective Inhibition of PDE4B Reduces Binge Drinking in Two C57BL/6 Substrains
C. Leonardo Jimenez Chavez, Camron D. Bryant, Melissa A. Munn‐Chernoff, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5443-5443
Open Access | Times Cited: 16
Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia
Santiago G. Lago, Sabine Bahn
ACS Chemical Neuroscience (2018) Vol. 10, Iss. 1, pp. 58-78
Closed Access | Times Cited: 18
Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia
Mayasah Al‐Nema, Anand Gaurav
Current Topics in Medicinal Chemistry (2020) Vol. 20, Iss. 26, pp. 2404-2421
Closed Access | Times Cited: 15
Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress
Harsh S. Amin, Palak K. Parikh, Manjunath Ghate
European Journal of Medicinal Chemistry (2021) Vol. 214, pp. 113155-113155
Closed Access | Times Cited: 11
GenomeMUSter mouse genetic variation service enables multi-trait, multi-population data integration and analyses
Robyn L. Ball, Molly A. Bogue, Hongping Liang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Transcriptome-wide association study of Alzheimer disease reveals many differentially expressed genes and multiple biological pathways in brain tissue from African American donors
Mark W. Logue, Adam Labadorf, Nicholas K. O’Neill, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Alpha 7 nicotinic receptor agonist and positive allosteric modulators improved social and molecular deficits of MK-801 model of schizophrenia in rats
Gökhan Ünal, Hatice Bekçi, Ahmet Cumaoğlu, et al.
Pharmacology Biochemistry and Behavior (2020) Vol. 193, pp. 172916-172916
Closed Access | Times Cited: 11
Selective Inhibition of PDE4B Reduces Methamphetamine Reinforcement in Two C57BL/6 Substrains
Kevin M. Honeywell, Eliyana Van Doren, Karen K. Szumlinski
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4872-4872
Open Access | Times Cited: 7
Treatments for Social Interaction Impairment in Animal Models of Schizophrenia: A Critical Review and Meta-analysis
Reut Hazani, Michal Lavidor, Aron Weller
Schizophrenia Bulletin (2022) Vol. 48, Iss. 6, pp. 1179-1193
Open Access | Times Cited: 7
Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies
Agnieszka Jankowska, Grzegorz Satała, Anna Partyka, et al.
Current Medicinal Chemistry (2019) Vol. 26, Iss. 25, pp. 4885-4913
Closed Access | Times Cited: 9
Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents
Misae Takakuwa, Yumi Watanabe, Kiichi Tanaka, et al.
Pharmacology Biochemistry and Behavior (2019) Vol. 185, pp. 172757-172757
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top